Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2008 | 1 |
2013 | 1 |
2014 | 1 |
2025 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Leuk Lymphoma. 2014 Jun;55(6):1332-6. doi: 10.3109/10428194.2013.838764. Epub 2013 Nov 1.
Leuk Lymphoma. 2014.
PMID: 24015841
Free PMC article.
Clinical Trial.
Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.
Wei X, Dai G, Liu Z, Cheng H, Xie Z, Marcucci G, Chan KK.
Wei X, et al.
AAPS J. 2006;8(4):E743-55. doi: 10.1208/aapsj080484.
AAPS J. 2006.
PMID: 17285740
Free PMC article.
Item in Clipboard
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G.
Klisovic RB, et al.
Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109.
Clin Cancer Res. 2008.
PMID: 18559610
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.